Achillion Pharmaceuticals (ACHN) has been under a strong bear grip, hence the stock is down -2.64% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 9.68% in the past 1 week. The stock has risen by 10.15% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.22% in the past 4 weeks.
Achillion Pharmaceuticals (NASDAQ:ACHN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.58 and $8.58 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.12, notching a gain of 6.67% for the day. The total traded volume was 1,312,001 . The stock had closed at $8.55 on the previous day.
The stock has recorded a 20-day Moving Average of 5.2% and the 50-Day Moving Average is 4.09%. Achillion Pharmaceuticals, Inc. is up 15.15% in the last 3-month period. Year-to-Date the stock performance stands at -15.48%.
Achillion Pharmaceuticals (ACHN) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $4. The average forecast of all the analysts is $9.25 and the expected standard deviation is $3.77.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.